Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Viral Infections

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

Abstract

PCR-based preemptive therapy with ganciclovir has been shown to reduce the incidence of CMV disease after BMT. Failures of this treatment strategy are CMV disease and secondary non-viral infections. Eighty-six consecutive patients at high risk for CMV disease who received PCR-based preemptive therapy with ganciclovir were assessed for treatment failures and possible risk factors. Ganciclovir was initiated in 57 of 86 patients (66%). Only 28 of 86 (32%) patients received 4 or more weeks of ganciclovir. Recurrence of CMV infection after successful treatment was more frequent among recipients of a BMT from an unrelated compared to a sibling donor (P = 0.004). three (3.5%) patients developed non-fatal early onset cmv disease and seven of 68 (10.3 %) late onset cmv disease (>100 days post transplant). Risk factors for late onset CMV disease were cGVHD (P = 0.0017) and duration of prior antiviral therapy >4 weeks (P = 0.0073). The incidence of secondary non-viral infections was 28% with the duration of antiviral treatment being a significant risk factor for secondary bacterial (P = 0.0045) and invasive fungal infections (P = 0.006). Thus, PCR-based preemptive treatment with ganciclovir reduces early onset CMV disease, but the duration of antiviral therapy prior to day +100 is a significant risk factor for late onset CMV disease as well as secondary non-viral infections. Bone Marrow Transplantation (2000) 25, 757–763.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human bone marrow transplantation J Infect Dis 1986 153: 478–488

    Article  CAS  PubMed  Google Scholar 

  2. Goodrich JM, Bowden RA, Fisher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic BMT Ann Intern Med 1993 118: 173–178

    Article  CAS  PubMed  Google Scholar 

  3. Winston DJ, Winston GH, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients Ann Intern Med 1993 118: 179–184

    Article  CAS  PubMed  Google Scholar 

  4. Schmidt GM, Horac DA, Niland JC et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants New Engl J Med 1991 324: 1005–1011

    Article  CAS  PubMed  Google Scholar 

  5. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation New Engl J Med 1991 325: 1601–1607

    Article  CAS  PubMed  Google Scholar 

  6. Van der Bij W, Schirm J, Torensma R et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes J Med Virol 1988 25: 179

    Article  CAS  PubMed  Google Scholar 

  7. Jiwa JM, Van Gemert GW, Raap AK et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction Transplantation 1989 48: 72–76

    Article  CAS  PubMed  Google Scholar 

  8. Einsele H, Steidle H, Vallbracht A et al. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique Blood 1991 77: 1104–1110

    CAS  PubMed  Google Scholar 

  9. Einsele H, Ehninger G, Steidle M et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease Lancet 1991 338: 1170–1172

    Article  CAS  PubMed  Google Scholar 

  10. Bacigalupo A, Van Lint MT, Tedone E et al. Early treatment of CMV infection in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir Bone Marrow Transplant 1994 13: 753–758

    CAS  PubMed  Google Scholar 

  11. Boeckh M, Bowden RA, Goodrich J et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic bone marrow transplantation Blood 1992 80: 1358–1364

    CAS  PubMed  Google Scholar 

  12. Ljungman P, Lore K, Aschan J et al. Use of a semiquantitative PCR assay for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients Bone Marrow Transplant 1996 17: 583–587

    CAS  PubMed  Google Scholar 

  13. Einsele H, Ehninger G, Hebart H et al. PCR-monitoring after BMT to reduce the incidence of CMV disease and the duration and side effects of antiviral therapy Blood 1995 86: 2815–2820

    CAS  PubMed  Google Scholar 

  14. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of HLA-matched sibling donors Transplantation 1974 18: 295–304

    Article  CAS  PubMed  Google Scholar 

  15. Lanino E, Anasetti C, Longton G et al. Prevention of cytomegalovirus disease with ganciclovir in recipients of marrow transplants from unrelated donors Blood 1993 82: (Suppl. 1) 1359 (Abstr.)

    Google Scholar 

  16. Li CR, Greenberg PD, Gilbert MJ et al. HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis Blood 1994 83: 1971–1979

    CAS  PubMed  Google Scholar 

  17. Canpolat C, Culbert S, Gardner M et al. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients Bone Marrow Transplant 1996 17: 589–593

    CAS  PubMed  Google Scholar 

  18. Przepiorka D, Ippoliti C, Panina J et al. Ganciclovir three times per week is not adequate to prevent CMV reactivation after T-cell depleted marrow transplantation Bone Marrow Transplant 1994 13: 461–464

    CAS  PubMed  Google Scholar 

  19. Atkinson K, Arthur C, Bradstock K et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients Bone Marrow Transplant 1995 16: 401–405

    CAS  PubMed  Google Scholar 

  20. Mandanas R, Saez RA, Selby GB, Confer DL . Cytomegalovirus surveillance and prevention in allogeneic bone marrow transplantation: examination of a preemptive plan of ganciclovir therapy Am J Hematol 1996 51: 104–111

    Article  CAS  PubMed  Google Scholar 

  21. Limaye AP, Bowden RA, Myerson D, Boeckh M . Cytomegalovirus disease occurring before engraftment in marrow transplant recipients Clin Infect Dis 1997 24: 830–835

    Article  CAS  PubMed  Google Scholar 

  22. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 1996 88: 4063–4071

    CAS  PubMed  Google Scholar 

  23. Yuen KY, Lo SKF, Chiu EKW et al. Monitoring of leukocyte cytomegalovirus DNA in bone marrow transplant recipients by nested PCR J Clin Microbiol 1995 33: 2530–2534

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Boeckh M, Bowden RA, Gooley T et al. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients Blood 1999 93: 1781–1782

    CAS  PubMed  Google Scholar 

  25. Boeckh M, Riddell SR, Cunningham T et al. Increased risk of late onset CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMV-specific T cell responses Blood 1996 88: (Suppl. 1) 302a (Abstr. 1195)

    Google Scholar 

  26. Zaia JA, Gallez-Hawkins GM, Tegtmeier BR et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma J Infect Dis 1997 176: 782–785

    Article  CAS  PubMed  Google Scholar 

  27. Singhal S, Mehta J, Powles R . Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet Blood 1994 84: 2055–2056

    CAS  PubMed  Google Scholar 

  28. Bowden RA, Digel J, Reed EC, Meyers JD . Immunosuppressive effects of ganciclovir on in vitro lymphocyte responses J Infect Dis 1985 156: 899–903

    Article  Google Scholar 

  29. Krause H, Hebart H, Jahn G et al. Screening for CMV-specific T-cell proliferation to identify patients at risk to develop late onset CMV disease Bone Marrow Transplant 1997 19: 1111–1116

    Article  CAS  PubMed  Google Scholar 

  30. Riddell SR, Watanabe KS, Goodrich JM et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones Science 1992 257: 238–241

    Article  CAS  PubMed  Google Scholar 

  31. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor New Engl J Med 1996 333: 1038–1044

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by the Deutsche Forschungsgemeinschaft (DFG), SFB 510, project B3.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Einsele, H., Hebart, H., Kauffmann-Schneider, C. et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 25, 757–763 (2000). https://doi.org/10.1038/sj.bmt.1702226

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702226

Keywords

This article is cited by

Search

Quick links